ArticlesMortality risk among sulfonylureas: a systematic review and network meta-analysis
Introduction
Sulfonylureas are recommended in clinical practice guidelines for management of patients with type 2 diabetes because they effectively lower blood glucose and reduce the risk of microvascular complications such as nephropathy and retinopathy.1, 2, 3 However, debate regarding the cardiovascular safety of sulfonylureas is ongoing.4 Findings from several studies and meta-analyses suggest that sulfonylureas are associated with a significantly higher risk of mortality and adverse cardiovascular events than metformin and other antidiabetic drugs.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Two mechanisms are often proposed to explain the higher risk of adverse cardiovascular effects associated with sulfonylureas. The first plausible biological mechanism centres on an extension of the beneficial pharmacological action of sulfonylureas. These drugs bind to sulfonylurea receptors (SUR1) on pancreatic β cells and inhibit ATP-sensitive potassium channels; this process promotes insulin release and lowers blood glucose concentrations.16 However, sulfonylureas also bind to receptors on myocardial (SUR2A) and vascular smooth muscle (SUR2B) cells, so can inhibit cardiac ATP-sensitive potassium channels.16, 17 Binding of sulfonylureas to SUR2A or SUR2B receptors can interfere with ischaemic conditioning—an endogenous cardiac protective mechanism—and possibly with cardiac conduction.18, 19 Findings from studies of animal models have shown that sulfonylureas binding to SUR2A or SUR2B receptors can abolish the beneficial effects of ischaemic conditioning.20, 21 The affinity characteristics seem to vary among sulfonylureas towards SUR1, SUR2A, and SUR2B, with some—such as gliclazide—binding selectively to SUR1 when given at usual therapeutic doses, and others—such as glibenclamide—binding to sulfonylurea receptors in both the heart and pancreas when given at therapeutic doses.16, 19, 22
The second plausible mechanism for the higher risk of adverse cardiovascular effects associated with sulfonylureas involves hypoglycaemia—a common, well known adverse effect of sulfonylurea treatment. Episodes of hypoglycaemia can prolong the QT interval and are associated with cardiac ischaemia.23, 24 A prolonged QT interval and cardiac ischaemia can increase the risk of adverse cardiovascular events, such as ventricular arrhythmias, myocardial infarction, and sudden cardiac death.25 Differences in SUR1 receptor affinity and pharmacokinetic properties seem to create differences in the risk of hypoglycaemia, with glibenclamide, which has the highest affinity for SUR1,22 having the highest risk among the sulfonylureas.26, 27 Other mechanisms that might explain the increased risk of cardiovascular events with sulfonylureas compared with other antidiabetic drugs include increased secretion of intact proinsulin, increased amount of visceral adipose tissue, and weight gain.28, 29
Despite this controversy regarding cardiovascular safety, sulfonylureas remain the most commonly used second-line oral antidiabetic drugs in patients with type 2 diabetes when metformin monotherapy does not successfully control blood glucose or is contraindicated.30, 31, 32, 33 Regardless of the mechanism, assessment of whether the risk of adverse cardiovascular events is similar among sulfonylureas is important. Ideally, the question of relative cardiovascular safety among sulfonylureas should be tested in a randomised controlled trial. Although seven studies have randomly allocated patients to more than one sulfonylurea and reported deaths or cardiovascular events, there are important limitations to this source of evidence.3, 34, 35, 36, 37, 38, 39 First, the UK Prospective Diabetes Study (UKPDS)3 was the only trial to report cardiovascular events as prespecified outcomes. Second, the remaining six randomised controlled trials34, 35, 36, 37, 38, 39 were not designed to examine risk of adverse cardiovascular events and therefore had insufficient power because of small sample sizes (30–1044 patients enrolled), short follow-up (median 6 months), and few reported events (24 deaths in total). In the absence of definitive evidence from randomised controlled trials, observational studies and meta-analyses of these data can provide information to help guide treatment decisions.40
Network meta-analyses are regarded as an important source of information to compare the safety or efficacy of several treatment options.41 This analytical technique is increasingly used to synthesise evidence from both direct and indirect comparisons to assess the effect of different treatment options on an outcome of interest.42, 43
We undertook a network meta-analysis to compare the relative risk of mortality and adverse cardiovascular events among sulfonylureas. On the basis of our previous findings,22, 44 we hypothesised that gliclazide use would be associated with a significantly lower risk of mortality and adverse cardiovascular events compared with glibenclamide use.
Section snippets
Search strategy and selection criteria
We followed standard methodology to undertake and report a systematic review and network meta-analysis.45, 46, 47, 48 We searched Medline and Embase from inception to June 11, 2014, with database-appropriate terms and text words for type 2 diabetes, sulfonylureas, and comparative study; we excluded review articles, editorials, commentaries, and animal studies (appendix). We supplemented the electronic database search by examining reference lists of potentially relevant studies and review
Results
The literature search identified 5669 unique citations; after screening the titles and abstracts, 469 papers were deemed potentially relevant (figure 1). We requested additional information from the authors of 46 studies (9·8%) and disagreed on the inclusion of eight (1·7%) articles. 24 studies met all inclusion criteria.
The table summarises characteristics of the seven studies that randomly allocated patients to different sulfonylureas3, 34, 35, 36, 37, 38, 39 and 17 observational studies in
Discussion
In this systematic review, we identified 24 controlled studies that reported the risk of adverse cardiovascular outcomes for two or more sulfonylureas. We were able to combine mortality data from 23 of these studies that enrolled a total of 172 349 patients who used a sulfonylurea; 18 of these studies (167 327 patients) were included in our main analyses. In all direct or direct and indirect analyses, gliclazide use was associated with a significantly lower risk of all-cause and
References (74)
- et al.
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
J Am Coll Cardiol
(1999) - et al.
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Lancet
(2012) - et al.
Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels
J Diabetes Complications
(2000) - et al.
Sulfonylureas and the risk of myocardial infarction
Metabolism
(2006) - et al.
Use patterns of antidiabetic regimens by patients with type 2 diabetes
Can J Diabetes
(2013) - et al.
Type 2 diabetes mellitus management in Canada: is it improving?
Can J Diabetes
(2013) - et al.
Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment
Metabolism
(1992) - et al.
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2
Value Health
(2011) - et al.
Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction—a nationwide study
Int J Cardiol
(2011) - et al.
Meta-analysis in clinical trials
Cont Clin Trials
(1986)
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study
Diabetes Res Clin Pract
Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction
Mayo Clin Proc
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial
Nutr Metab Cardiovasc Dis
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Lancet
Pharmacologic management of type 2 diabetes
Can J Diabetes
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet
Do sulfonylurea drugs increase the risk of cardiac events?
Can Med Assoc J
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
Diabetes Care
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Diabetologia
The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis
Diabetes Care
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies
Diabetes Care
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review
Arch Intern Med
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies
Diab Vasc Dis Res
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Cochrane Database Syst Rev
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
Diabetes Obes Metab
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
Diabet Med
Preconditioning: a paradigm shift in the biology of myocardial ischemia
Am J Physiol Heart Circ Physiol
Preconditioning and postconditioning: new strategies for cardioprotection
Diabetes Obes Metab
Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
Circ Res
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes
Diabetologia
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
Diabetes Obes Metab
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
J Intern Med
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring
Diabetes Care
The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia
Acta Diabetol
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
Eur J Clin Invest
A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin
Diabetes Care
Cited by (178)
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
2022, Diabetes and MetabolismCitation Excerpt :This may explain why so many discordant findings were reported in the literature. Furthermore, SU pharmacological class is heterogeneous, including compounds with different properties and also potentially different risks of mortality [46]. Glibenclamide (glyburide), unlike metformin, causes prolongation of QTc and an increase in QT dispersion in patients with T2DM [36].
Treatment of type 2 diabetes
2024, DiabetologieDipeptidyl peptidase-4 inhibitors versus sulfonylureas on the top of metformin in patients with diabetes and acute myocardial infarction
2024, Cardiovascular Diagnosis and TherapyGenetics and epigenetics of diabetes and its complications in India
2024, Human Genetics